<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568200</url>
  </required_header>
  <id_info>
    <org_study_id>69152630</org_study_id>
    <nct_id>NCT04568200</nct_id>
  </id_info>
  <brief_title>Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Prospective, Randomized Controlled Study to Evaluate the Efficacy and Safety of Durvalumab Combined With Neoadjuvant Therapy in Patients With Local Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of preoperative treatment with durvalumab&#xD;
      combined with neoajuvant therapy (carboplatin, paclitaxel with/without radiation) in locally&#xD;
      advanced resectable oesophageal squamous carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to assess the tumor response (by irRECIST) and&#xD;
      pathological response of preoperative treatment with durvalumab combined with neoadjuvant&#xD;
      therapy (carboplatin, paclitaxel with/without radiation).&#xD;
&#xD;
      Secondary objectives are:&#xD;
&#xD;
      To assess completion of treatment with durvalumab combined with chemotherapy with/without&#xD;
      radiation treatment.&#xD;
&#xD;
      To assess toxicities of durvalumab in combination with chemoradiation. [Time Frame: up to 1&#xD;
      year] To assess completion of chemotherapy with/without radiation treatment. To assess&#xD;
      withdrawal rate from surgery. To assess delay rate from surgery. To assess R0 resection rate.&#xD;
      To assess post-operative complications. Progression Free Survival. [ Time Frame: up to 24&#xD;
      months ] Overall Survival. [ Time Frame: up to 24 months ]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>assess the tumor response (by irRECIST) of preoperative treatment with durvalumab combined with neoadjuvant therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathological response</measure>
    <time_frame>up to 12 months</time_frame>
    <description>assess the pathological response (by CAP classification) of preoperative treatment with durvalumab combined with neoadjuvant therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage completion of treatment with durvalumab combined with chemotherapy with/without radiation treatment</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage completion of treatment with durvalumab combined with chemotherapy with/without radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of toxicity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Incidence and severity of toxicity defined to CTCAE v4.03 and Radiation Oncology Group (RTOG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage completion of chemotherapy with/without radiation treatment</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage completion of chemotherapy with/without radiation treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage withdrawal rate from surgery due to durvalumab related complications</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage withdrawal rate from surgery due to durvalumab related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage delay of surgery due to durvalumab related complications</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Percentage delay of surgery due to durvalumab related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 3 months</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of post-operative complications to the Dindo classification</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence and severity of post-operative complications to the Dindo classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>durvalumab and neoadjuvant therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>durvalumab 1500mg i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline and neoadjuvant therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 500ml i.v. day 1-22-43-64 Carboplatin AUC = 4-5 i.v day 1-22-43-64 Paclitaxel 75 mg/m2 i.v day 1-22-43-64 with/without Radiotherapy 23 x 1.8 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500mg i.v. day 1-22-43-64</description>
    <arm_group_label>durvalumab and neoadjuvant therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>durvalumab and neoadjuvant therapy</arm_group_label>
    <arm_group_label>normal saline and neoadjuvant therapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>durvalumab and neoadjuvant therapy</arm_group_label>
    <arm_group_label>normal saline and neoadjuvant therapy</arm_group_label>
    <other_name>Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy 23 x 1.8 Gy</intervention_name>
    <description>Radiotherapy 23 x 1.8 Gy</description>
    <arm_group_label>durvalumab and neoadjuvant therapy</arm_group_label>
    <arm_group_label>normal saline and neoadjuvant therapy</arm_group_label>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the esophagus.&#xD;
&#xD;
          -  Surgical resectable (T3 or T4b, N0 or N+, M0), as determined by Endoscopic Ultra Sound&#xD;
             (EUS),PET/CT, Esophageal MRI and enhanced CT scan of neck, thorax and abdomen.&#xD;
&#xD;
          -  Tumor length longitudinal ≤ 10 cm; if larger than 10 cm, inclusion should be discussed&#xD;
             with the principal investigator.&#xD;
&#xD;
          -  18≤Age≤75.&#xD;
&#xD;
          -  Tumor does not involve gastro-esophageal junction.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic functions defined as:&#xD;
&#xD;
        neutrophiles ≥ 1.5 x 109/L platelets ≥ 100 x 109/L alanine transaminase≤2 x upper normal&#xD;
        limit hemoglobin ≥ 5.6 mmol total bilirubin ≤ 1.5 x upper normal limit creatinine clearance&#xD;
        (Cockroft) ≥60 ml/min&#xD;
&#xD;
          -  Written, voluntary informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past or current history of malignancy other than entry diagnosis interfering with&#xD;
             prognosis of esophageal cancer.&#xD;
&#xD;
          -  T1, T2 tumors or in situ carcinoma.&#xD;
&#xD;
          -  metastatic oesophageal cancer.&#xD;
&#xD;
          -  Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.&#xD;
&#xD;
          -  Previous chemotherapy, radiotherapy, and/or treatment with checkpoint inhibitors.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (including myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) precluding major surgery.&#xD;
&#xD;
          -  Pulmonary fibrosis and/or severely impaired lung function precluding major surgery.&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity greater than WHO grade 1.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs).&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (&gt;10&#xD;
             mg/day prednisone or equivalent) or any other form of immunosuppressive therapy within&#xD;
             7 days prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Dementia or altered mental status that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  Serious underlying medical condition which would impair the ability of the patient to&#xD;
             receive the planned treatment, including prior allergic reactions to drugs containing&#xD;
             Cremophor, such as teniposide or cyclosporine.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy which has not resolved 3 days&#xD;
             (simple infection such as cystitis) to 7 days (severe infection such as&#xD;
             pyelonephritis) prior to the first dose of trial treatment.&#xD;
&#xD;
          -  Has a diagnosis of acute or chronic hepatitis B, hepatitis C, known immunodeficiency&#xD;
             or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Patients with prior allogeneic stem cell or solid organ transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia He, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jia He, MD</last_name>
    <phone>+86-13810096213</phone>
    <email>hejia@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luo Zhao, MD</last_name>
    <phone>+86-18519667758</phone>
    <email>zhaoluo@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia He, MD</last_name>
      <phone>+86-13810096213</phone>
      <email>hejia@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Luo Zhao, MD</last_name>
      <phone>+86-18519667758</phone>
      <email>Zhaoluo@pumch.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

